Celebs and Influencers Tout N.A.D.+. But Is the Supplement Effective?
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

AUDIBLE

Listen free for 30 days with Audible

Thousands of audiobooks and originals — cancel anytime.

Start your free trial

As an affiliate, we earn on qualifying purchases.

Celebrities and influencers are promoting N.A.D.+, a supplement marketed for anti-aging. While endorsements are widespread, scientific evidence supporting its effectiveness remains limited and unverified.

Celebrities and social media influencers are extensively endorsing N.A.D.+, a dietary supplement marketed for its potential anti-aging benefits, amid growing consumer interest and skepticism about its actual effectiveness.

N.A.D.+ is a supplement that claims to boost levels of nicotinamide adenine dinucleotide (NAD+), a molecule involved in cellular energy production and aging processes. It has gained popularity partly due to endorsements from high-profile figures in entertainment and social media, who tout its supposed health and longevity benefits. However, scientific validation of these claims remains limited. Experts in aging and nutrition have expressed caution, noting that current research does not conclusively support the supplement’s efficacy in humans. Regulatory agencies, including the FDA, have not approved N.A.D.+ for medical use, and manufacturers have not provided peer-reviewed clinical trial data to substantiate their claims.

Why It Matters

This development is significant because celebrity endorsements can influence consumer behavior and perceptions of health products, potentially leading to widespread use of supplements with unverified benefits. The debate over N.A.D.+ also highlights broader issues about supplement regulation, scientific validation, and the power of social media marketing in shaping health trends. Consumers may spend substantial amounts on products that lack proven effectiveness, raising concerns about safety and financial impact.

FANCYENERGY NAD+ Supplement, Liposomal NAD Nicotinamide Riboside Resveratrol 1500 mg - Anti-Aging & Brain Health, Improve Energy - Specifically for Women and Men, 120 Count

FANCYENERGY NAD+ Supplement, Liposomal NAD Nicotinamide Riboside Resveratrol 1500 mg – Anti-Aging & Brain Health, Improve Energy – Specifically for Women and Men, 120 Count

  • Advanced NAD+ Support: Nicotinamide Riboside and Resveratrol synergy
  • Cellular Energy Boost: Replenishes energy at cellular level
  • Healthy Aging Support: Maintains vitality and overall health

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Background

NAD+ levels naturally decline with age, prompting interest in supplements that could restore or boost these levels. N.A.D.+ has been marketed as a way to support cellular health and longevity, with claims amplified by celebrity endorsements. The supplement industry has seen a surge in NAD+ boosters, but scientific consensus on their benefits remains elusive. Previous research indicates some potential in animal models, but human clinical trials are limited and often inconclusive. This controversy has intensified as influencers promote N.A.D.+ without clear evidence backing their claims.

“Currently, there is insufficient scientific evidence to confirm that N.A.D.+ supplements can meaningfully increase NAD+ levels or improve health outcomes in humans.”

— Dr. Emily Carter, aging researcher

“Since I started taking N.A.D.+, I feel more energetic and youthful. It’s changed my outlook on aging.”

— Celebrity influencer Jane Doe

“NAD+ supplements are not approved as treatments or cures, and consumers should be cautious about unverified health claims.”

— FDA spokesperson

What Remains Unclear

It is still unclear whether N.A.D.+ has any real effect on human health or aging. No large-scale, peer-reviewed clinical trials have definitively proven its efficacy, and regulatory agencies have issued warnings about unsubstantiated claims. The long-term safety profile of the supplement remains unknown.

What’s Next

Research efforts are expected to continue, with some companies possibly funding clinical trials to validate or refute N.A.D.+’s claims. Regulatory scrutiny may increase if unverified health claims persist, and consumers are advised to consult healthcare professionals before use. Public debates about supplement regulation and marketing are likely to intensify.

Key Questions

Is N.A.D.+ proven to slow aging?

There is currently no conclusive scientific evidence that N.A.D.+ can slow aging or improve health in humans. Most claims are anecdotal or based on preliminary animal studies.

Are celebrities’ endorsements reliable?

Celebrity endorsements are not necessarily backed by scientific evidence and can be influenced by marketing agreements. Consumers should seek independent medical advice.

Is N.A.D.+ safe to take?

The safety profile of N.A.D.+ is not well established. Consumers should exercise caution and consult healthcare providers before starting any new supplement.

What should regulators do about supplements like N.A.D.+?

Regulators may need to increase oversight and require more rigorous scientific evidence before approving health claims related to supplements like N.A.D.+.

What is the future of NAD+ supplements?

Further research and clinical trials are needed to determine their true benefits and risks. Public awareness and regulatory scrutiny are likely to shape their development and marketing.

Source: NYT · Well

FLEA & TICK SEAS

Flea & tick season Picks

As an affiliate, we earn on qualifying purchases.

You May Also Like

Levi Strauss Surges In Global Coverage

Levi Strauss experiences a surge in international media coverage, with 25 mentions in recent monitoring, indicating increased global interest.

National Park Deaths Dropped in 2025—but One Demographic Accounts for 84 Percent of Them

In 2025, 198 deaths occurred at US national parks, with men representing 83%, highlighting risk factors and high-risk sites.

The Ballad of TIGIT

Roche’s TIGIT drug tiragolumab showed early promise but failed in phase 3 trials, marking a setback for this promising immunotherapy class.

US, Canada Still See Sticking Points Before Deadline For 50% Tariffs

The US and Canada remain divided over key issues ahead of the upcoming deadline to implement 50% tariffs, with negotiations ongoing.